Brihans Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 03-12-2024
- Paid Up Capital ₹ 0.10 M
as on 03-12-2024
- Company Age 21 Year, 27 Days
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 4.10 Cr
as on 03-12-2024
- Revenue %
(FY 2022)
- Profit -168.94%
(FY 2022)
- Ebitda -1443.66%
(FY 2022)
- Net Worth -0.09%
(FY 2022)
- Total Assets -1.06%
(FY 2022)
About Brihans Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹4.10 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Uttam Tendulkar and Umesh Joshi serve as directors at the Company.
- CIN/LLPIN
U24232PN2003PTC018603
- Company No.
018603
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Nov 2003
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Solapur, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Brihans Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Uttam Tendulkar  | Director | 27-Nov-2003 | Current |
| Umesh Joshi | Director | 30-Jul-2021 | Current |
Financial Performance of Brihans Pharmaceuticals.
Brihans Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 168.94% decrease in profit. The company's net worth dipped by a decrease of 0.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Brihans Pharmaceuticals?
In 2019, Brihans Pharmaceuticals had a promoter holding of 99.98% and a public holding of 0.02%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Baumgarten & Walia (Bottling) Private LimitedActive 49 years 8 monthsUmesh Joshi is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Shree Suvarna Sahakari Bank Ltd. Creation Date: 27 Mar 2004 | ₹4.10 Cr | Satisfied |
How Many Employees Work at Brihans Pharmaceuticals?
Brihans Pharmaceuticals has a workforce of 0 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Brihans Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Brihans Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
